This trial studied the safety of a drug for long-term use to help with presbyopia (age-related vision problems).
- Near Vision
- Constricted Pupil
- Eye Diseases
1 Primary · 0 Secondary · Reporting Duration: 7 visits over a total duration of approximately 28 weeks
3 Treatment Groups
Combination ophthalmic solution (LNZ101) dosed bilaterally
1 of 3
Aceclidine ophthalmic solution dosed bilaterally
1 of 3
Placebo (Vehicle) ophthalmic solution dosed bilaterally
1 of 3
300 Total Participants · 3 Treatment Groups
Primary Treatment: Combination ophthalmic solution (LNZ101) dosed bilaterally · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 45 - 75 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could I potentially participate in this clinical experiment?
"This trial seeks to enrol 300 participants aged between 45 and 75 years old with presbyopia." - Anonymous Online Contributor
Are applicants younger than 85 years of age being accepted into this research?
"The prerequisites for this experiment restrict the participants to being between 45 and 75 years of age. Additionally, there are 11 trials available for those below 18 and 117 options for individuals over 65." - Anonymous Online Contributor
Are any new volunteers being accepted for this research initiative?
"According to the information on clinicaltrials.gov, this medical investigation is actively recruiting participants. The study was first advertised on February 21st 2023 and has since been amended (most recently March 2nd 2023)." - Anonymous Online Contributor
How many participants have registered for this research endeavor?
"Affirmative. Per clinicaltrials.gov, this research venture is presently searching for volunteers; the study was originally posted on February 21st 2023 and refreshed lastly on March 2nd 2023. 300 people are expected to be enrolled at two distinct centres." - Anonymous Online Contributor
What side effects have been observed with the bilaterally administered Combination ophthalmic solution (LNZ101)?
"Our organisation has rated Combination ophthalmic solution (LNZ101) dosed bilaterally a 3 on the safety scale due to both efficacy evidence and numerous rounds of data supporting its security." - Anonymous Online Contributor